toxicity from PCZ. 5, [7] [8] [9] However, real-world data are lacking regarding use of ISA after PCZ toxicity.
| PATIENTS AND ME THODS
We reviewed the electronic medical records of all adult leukaemia QTc interval on ECG. All toxicity grading was performed using the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. 10 The study was approved by the MDACC Institutional
Review Board, and conducted in accordance with the Declaration of Helsinki.
| RE SULTS
We identified 23 patients, of which 20 patients had evidence of azole-induced hepatotoxicity and three patients had Grade 3/4
QTc prolongation on ECG while on PCZ. The median age was 67 years (range, 23-84 years; Table 1 ). The majority of patients (87%) had acute myeloid leukaemia (AML), and all except one patient (96%) received chemotherapy within the 3 months prior to initiating ISA. The majority (70%) of patients had relapsed or refractory leukaemia, while 17% were undergoing first induction with chemotherapy. Three patients (13%) had a prior alloSCT at the time of ISA initiation. ISA was given for treatment of IFI in 18 out of the 23 patients (78%). The majority of these patients were critically ill and severely immunocompromised, with 13 patients having an ANC <500 cells/mm 3 at the time of ISA initiation. Of the 20 patients with azole-induced hepatotoxicity, baseline ChildPugh scores before PCZ administration were 35% Class A (n = 7)
and 65% Class B (n = 13) and no patients had clinical stigmata of chronic liver disease. The median time to PCZ toxicity was 16 days (range 3-331 days) with only three patients experiencing toxicity during the first week of therapy. Of the 20 patients with evidence of hepatotoxicity while on PCZ, the number of patients with Grade 3/4 elevations in LFTs was decreased after changing to ISA (30% after PCZ vs 5% after ISA; Table 2 ). Specifically, the median total bilirubin (2.05 vs Table S1 ).
One patient had Grade 3 elevation in all LFTs with PCZ which resolved to Grade 1 (total bilirubin), Grade 2 (ALT) and Grade 1 (AST) after switching to ISA (Table 2 ). Two additional patients had Grade 3 elevations in both ALT and AST with PCZ, which resolved to normal limits after switching to ISA (Table 2) . Posaconazole serum trough levels were available for 17 out of the 23 patients within 2 weeks prior to switching to ISA due to PCZ toxicity. There was no apparent association between PCZ toxicity and PCZ serum trough levels in these patients. Specifically, for the 15 patients with liver toxicity who had PCZ levels, the median level was 1420 ng/mL (range 523-3420 ng/mL), with only five patients having a PCZ level >2000 ng/mL. The PCZ level for the patient with cardiac arrest and PEA along with QTc prolongation was 2570 ng/ mL; however, the PCZ level for the patient with asymptomatic Grade | 83
Isavuconazole was used to treat presumed (n = 14) or documented (n = 4) IFI in the majority of patients. In addition to toxicity, three patients antifungal therapy was changed from ISA due to concern for possible breakthrough IFI (b-IFI). The 30-day mortality in our patients was 22% (five patients) and 60-day mortality was 30%
(seven patients) after switching to ISA therapy ( Table 1 ). The cause of death in the majority of patients was multi-organ failure in the setting of relapsed or refractory acute leukaemia, while three patients deceased with active confirmed IFI.
| D ISCUSS I ON
Here, we present the first published real-world data on ISA tolerability after PCZ toxicity with a focus on hepatotoxicity. We found ISA to be well-tolerated after PCZ toxicity with no patient discontinuing ISA due to toxicity. Specifically, liver toxicity as assessed by LFT values was reduced in all patients and QTc abnormalities resolved after switching PCZ to ISA.
The majority of patients who discontinued PCZ had hepatotoxicity, further characterising the complex interaction between antifungal treatment and liver toxicity. 9 Liver injury resulting from azole treatment is largely hepatocellular, but can be cholestatic or a mixture of both. 9 The relative incidence of severe liver toxicity is variable between antifungal agents with voriconazole and PCZ appearing to have greater incidence of Grade 3/4 increase in LFTs than fluconazole and itraconazole. 11 Although in our patients elevated LFTs are often due to many factors, such as the hematologic disease, chemotherapy treatment or from the underlying infection, studies estimate PCZ-associated liver injury occurs in ~5%-10% of patients. 7, 9 Voriconazole liver injury has been correlated with increased exposure and higher serum levels; however, PCZ liver injury has not been correlated with increased PCZ serum trough levels. 9, 12 Similarly, we did not find a correlation between PCZ levels and liver injury in our patients. Given the increased absorption of newer delayedrelease PCZ tablets, more investigation into correlation of PCZ levels and liver toxicity in the context of a therapeutic drug monitoring (TDM) setting is warranted. 61 patients resulted in significant reduction in LFTs. 13 Similarly, case reports and small retrospective studies utilising PCZ after voriconazole-induced liver toxicity showed resolution of previous liver injury with successful treatment of invasive aspergillosis. 5, 7, 8 These studies suggest hepatotoxicity to one azole does not predict future tolerability with other azoles, giving rationale to support switching therapy in this setting, although more investigations are needed. At present, it should be a patient-specific decision to change antifungal therapy based on laboratory markers of toxicity such as transaminitis. Several factors need to be considered such as the degree and rate of increase in LFTs, the clinical status of the patient, and the indication for antifungal use. QTc prolongation on other azoles is emerging.
14 Isavuconazole was used to treat presumed or documented IFI in 18 of our patients who had active leukaemia. Although efficacy of ISA for IFI is beyond the scope of this study, it is important to note that three patients antifungal therapy was changed from ISA due to concern for possible breakthrough IFI (b-IFI). Breakthrough IFIs during ISA therapy has been previously described in our patient population. 15 Breakthrough infections occurred in approximately 13% of patients on ISA therapy, mainly consisting of Candida spp and Mucorales. 15 Recent reports concerning the emergence of b-IFI while on ISA therapy are concerning and must be taken into consideration moving forward as ISA is being utilised more frequently especially in the immunocompromised patient.
Our study had several limitations, namely in view of its monocentric and retrospective nature with relatively few patients. In addition, we were unable to account for all confounding variables such as disease and performance status in these patients. Due to the small number of patients evaluated, it was difficult to assess the impact of rare side effects from azole treatment, such as neurotoxicity or adrenal dysfunction. 16, 17 In conclusion, ISA can be a safe alternative for IFIs in the setting of PCZ toxicity in heavily immunocompromised leukaemia patients.
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